202 related articles for article (PubMed ID: 9460289)
21. Non-enzymatic glycation in corneas from normal and diabetic donors and its effects on epithelial cell attachment in vitro.
McDermott AM; Xiao TL; Kern TS; Murphy CJ
Optometry; 2003 Jul; 74(7):443-52. PubMed ID: 12877277
[TBL] [Abstract][Full Text] [Related]
22. Binding of long-term glycated low density lipoprotein and AGE-albumin by peripheral monocytes and endothelial cells.
Sobal G; Sinzinger H; Menzel EJ
J Recept Signal Transduct Res; 1999; 19(1-4):267-81. PubMed ID: 10071763
[TBL] [Abstract][Full Text] [Related]
23. Modified lipoproteins in diabetes.
Deslypere JP
J Intern Med Suppl; 1994; 736():69-74. PubMed ID: 7986312
[TBL] [Abstract][Full Text] [Related]
24. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy.
Zhou H; Tan KC; Shiu SW; Wong Y
Nephrol Dial Transplant; 2008 Mar; 23(3):927-33. PubMed ID: 18065800
[TBL] [Abstract][Full Text] [Related]
25. [Non-enzymatic glycosylation. Biology. Pathology].
Lestradet H
Ann Pediatr (Paris); 1991 Apr; 38(4):229-34. PubMed ID: 2069357
[TBL] [Abstract][Full Text] [Related]
26. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
Kontush A; Chapman MJ
Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
[TBL] [Abstract][Full Text] [Related]
27. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
[TBL] [Abstract][Full Text] [Related]
28. Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages.
Brown BE; Rashid I; van Reyk DM; Davies MJ
FEBS J; 2007 Mar; 274(6):1530-41. PubMed ID: 17480204
[TBL] [Abstract][Full Text] [Related]
29. Diabetic dyslipidaemia.
Erkelens DW
Eur Heart J; 1998 Jul; 19 Suppl H():H27-40. PubMed ID: 9717062
[TBL] [Abstract][Full Text] [Related]
30. [Immune response against modified low-density lipoproteins in patients with non-insulin-dependent diabetes mellitus].
González M; Rojas N; Durán D; Schade A; Campos R; Milos C
Rev Med Chil; 1997 Aug; 125(8):879-85. PubMed ID: 9567390
[TBL] [Abstract][Full Text] [Related]
31. Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients.
Girona J; Manzanares JM; Marimón F; Cabré A; Heras M; Guardiola M; Ribalta J; Masana L
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):380-7. PubMed ID: 17904830
[TBL] [Abstract][Full Text] [Related]
32. Glycation of lipoproteins and accelerated atherosclerosis in non-insulin-dependent diabetes mellitus.
Yegin A; Ozben T; Yegin H
Int J Clin Lab Res; 1995; 25(3):157-61. PubMed ID: 8562980
[TBL] [Abstract][Full Text] [Related]
33. [Insulin, diabetes and cholesterol metabolism].
Monnier L; Colette C; Percheron C; Descomps B
C R Seances Soc Biol Fil; 1995; 189(5):919-31. PubMed ID: 8673637
[TBL] [Abstract][Full Text] [Related]
34. Glucose oxidation and low-density lipoprotein-induced macrophage ceroid accumulation: possible implications for diabetic atherosclerosis.
Hunt JV; Bottoms MA; Clare K; Skamarauskas JT; Mitchinson MJ
Biochem J; 1994 May; 300 ( Pt 1)(Pt 1):243-9. PubMed ID: 8198540
[TBL] [Abstract][Full Text] [Related]
35. Non-enzymatic glycation and protein recognition.
Bitensky MW; Kowluru A; Kowluru RA
Prog Clin Biol Res; 1989; 304():185-203. PubMed ID: 2675028
[TBL] [Abstract][Full Text] [Related]
36. Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes.
Cohen MP; Lautenslager G; Shea E
Eur J Clin Chem Clin Biochem; 1993 Nov; 31(11):707-13. PubMed ID: 7508270
[TBL] [Abstract][Full Text] [Related]
37. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation.
Babiy AV; Gebicki JM; Sullivan DR; Willey K
Biochem Pharmacol; 1992 Mar; 43(5):995-1000. PubMed ID: 1554398
[TBL] [Abstract][Full Text] [Related]
38. The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis.
Makita Z; Yanagisawa K; Kuwajima S; Bucala R; Vlassara H; Koike T
Nephrol Dial Transplant; 1996; 11 Suppl 5():31-3. PubMed ID: 9044304
[TBL] [Abstract][Full Text] [Related]
39. Synergetic effect of desialylated and glycated low density lipoproteins on cholesterol accumulation in cultured smooth muscle intimal cells.
Sobenin IA; Tertov VV; Orekhov AN; Smirnov VN
Atherosclerosis; 1991 Aug; 89(2-3):151-4. PubMed ID: 1793442
[TBL] [Abstract][Full Text] [Related]
40. Hyperglycemia, lipoprotein glycation, and vascular disease.
Veiraiah A
Angiology; 2005; 56(4):431-8. PubMed ID: 16079928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
